BioNTech starts Phase 3 trial of pumitamig plus Gilead's Trodelvy for breast cancer
GILD•BioNTech and Gilead will evaluate pumitamig with sacituzumab govitecan in a Phase 3 trial for first-line triple-negative breast cancer.
1. Phase 3 evaluation
BioNTech is advancing the ROSETTA BREAST-01 Phase 3 trial of pumitamig with Gilead’s sacituzumab govitecan in first-line triple-negative breast cancer. BioNTech will continue to sponsor and lead the trial, and Gilead will supply sacituzumab govitecan.
